All News

The Center on Health Equity and Access delivers current updates, highlights breakthroughs in research, and ongoing endeavors committed to addressing healthcare inequalities and improving universal access to exceptional health care.

Promoting health equity isn’t only about consideration of underlying health risks; it’s also about using that data to inform population care as well as give clinicians and their teams more time with the patient in front of them.

The authors suggest the phenomenon of 2 mutationally distinct diffuse large B-cell lymphomas (DLBCLs) might be more common than currently understood.

US women in low-income regions are experiencing a steep increase in cervical cancer diagnosis and death despite medical improvements; a Senate committee launches an assisted living examination, its first hearing on the industry in 2 decades; the CDC urges health care providers to be alert for patients who have fever, rashes, an traveled abroad following reports of 23 measles cases since December 1.

The phase 3 ASCERTAIN study found that orally administered decitabine and cedazuridine had similar pharmacologic effects compared with intravenously administered decitabine.

A claims-based study analyzing Medicare beneficiaries with multiple myeloma found that racial disparities still impact treatment in this patient population.

Pulling data from a US electronic health record–based database, researchers found low rates of complete remission and poor overall survival among 382 patients who had myelodysplastic syndromes (MDS) receiving first-line azacytidine (AZA).

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Investigators say attempts to overcome mutational resistance to Bruton’s tyrosine kinase (BTK) inhibitors have had mixed results among patients who have chronic lymphocytic leukemia (CLL).

Researchers found TET2 clonal hematopoiesis of indeterminate potential (CHIP) to be an independent risk factor associated with incident heart failure with preserved ejection fraction (HFpEF).

A comprehensive report exhibits how in-person, telephone-, and video-based care has trended from 2020-2023 within the US Department of Veterans Affairs health care system.

A study from China found that tofacitinib was an effective treatment for alopecia areata (AA), with most patients achieving complete or partial hair regrowth and experiencing tolerable side effects.

The expanded indication makes dupilumab the only approved treatment for eosinophilic esophagitis (EoE) in this age group.

A recent study found that use of optimal guideline-directed medical therapies after heart failure with reduced ejection fraction (HFrEF) diagnosis is low overall, but especially among female patients compared with male patients.

Dupilumab shows long-term efficacy across yearly seasons in patients with type 2 inflammatory asthma.

A record 21.3 million people signed up for health insurance this year using the Affordable Care Act (ACA) marketplaces; nearly 80% of health care providers think it is important for their hospital to minimize its environmental impact; the FDA noted a potential link between CAR-T products and the development of T-cell cancer.

The data suggest this burden among patients who have myasthenia gravis (MG) is prevalent across insurance types.

An analysis covered trends in mortality caused by diabetes and diabetic kidney disease across North, South, and Central America from 2000 to 2019.

A predictive model utilizing serum metabolic profiles was able to distinguish ovarian cancer from control samples with 93% accuracy, according to a new study.

A new study challenges assumptions about the role of dietary protein and fat in managing blood glucose fluctuations, known as glycemic variability.

MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.

OneOncology announces the appointment of new chair members of the OneCouncil Disease Group to begin service this year.

Patients with hemophilia A experienced prognostic and quality of life benefits from emicizumab (Hemlibra; Genentech) prophylaxis treatment.

Topline results from a pivotal phase 3, open-label extension study showcase the long-term safety and efficacy of olanzapine and samidorphan (Lybalvi) in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder.

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states.

A community-based study suggests a correlation between university education and the likelihood of disease-modifying therapy (DMT) uptake in multiple sclerosis (MS).

An analysis of the DELIVER trial also revealed an association between dapagliflozin treatment and reduced risk of cardiovascular death among individuals with heart failure with improved ejection fraction (HFimpEF).

Sarepta Therapeutics has started screening participants for a Phase 3 clinical trial to test its gene therapy candidate SRP-9003 in children with limb-girdle muscular dystrophy type 2E; wastewater testing points to a new COVID-19 infection wave fueled by the JN.1 variant; most patients on anti-obesity medications kept at least some weight off up to a year after they stopped taking them.

Global warming, wildfires, precipitation, floods, and storms impact patients with atopic dermatitis (AD).

The TROP-2–directed antibody drug conjugate is currently being investigated as a monotherapy and a combination therapy for non–small cell lung cancer (NSCLC) in 3 trials: phase 3 EVOKE-01, phase 2 EVOKE-02, and phase 3 EVOKE-03.